Reviewing Perspective Therapeutics (CATX) and Its Peers

Perspective Therapeutics (NASDAQ:CATX) is one of 28 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Perspective Therapeutics to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.

Institutional & Insider Ownership

54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Perspective Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Perspective Therapeutics’ competitors have a beta of 1.76, suggesting that their average stock price is 76% more volatile than the S&P 500.

Profitability

This table compares Perspective Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	N/A	N/A	N/A
Perspective Therapeutics Competitors	-672.41%	-133.75%	-59.01%

Analyst Recommendations

This is a summary of recent ratings for Perspective Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	6	0	3.00
Perspective Therapeutics Competitors	76	75	156	6	2.29

Perspective Therapeutics presently has a consensus target price of $11.17, suggesting a potential upside of 121.12%. As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 44.18%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Perspective Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares Perspective Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	-5.61
Perspective Therapeutics Competitors	$59.54 million	-$32.15 million	4.04

Perspective Therapeutics’ competitors have higher revenue, but lower earnings than Perspective Therapeutics. Perspective Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Perspective Therapeutics beats its competitors on 7 of the 12 factors compared.

Perspective Therapeutics Company Profile

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.